biostudies-literatureUnknown27(20)Barbier JWhen cells are exposed to a genotoxic stress, a DNA surveillance pathway that involves p53 is activated, allowing DNA repair. Eukaryotic cells have also evolved a mechanism called mRNA surveillance that controls the quality of mRNAs. Indeed, mutant mRNAs carrying premature translation termination codons (PTCs) are selectively degraded by the nonsense-mediated mRNA decay (NMD) pathway. However, in the case of particular genes, such as proto-oncogenes, mutations that do not create PTCs and therefore that do not induce mRNA degradation, can be harmful to cells. In this study, we showed that the H-ras gene in the absence of mutations produces an NMD-target splice variant that is degraded in the cytosol. We observed that a treatment with the genotoxic stress inducer camptothecin for 6 h favoredMolecular and cellular biology7315-33https://www.ebi.ac.uk/biostudies/studies/S-EPMC2168895biostudies-literatureRegulation of H-ras splice variant expression by cross talk between the p53 and nonsense-mediated mRNA decay pathways.PMC2168895Dutertre MAuboeuf Dde la Grange PBittencourt DSanchez GGratadou LBarbier JfalseRegulation of H-ras splice variant expression by cross talk between the p53 and nonsense-mediated mRNA decay pathways.When cells are exposed to a genotoxic stress, a DNA surveillance pathway that involves p53 is activated, allowing DNA repair. Eukaryotic cells have also evolved a mechanism called mRNA surveillance that controls the quality of mRNAs. Indeed, mutant mRNAs carrying premature translation termination codons (PTCs) are selectively degraded by the nonsense-mediated mRNA decay (NMD) pathway. However, in the case of particular genes, such as proto-oncogenes, mutations that do not create PTCs and therefore that do not induce mRNA degradation, can be harmful to cells. In this study, we showed that the H-ras gene in the absence of mutations produces an NMD-target splice variant that is degraded in the cytosol. We observed that a treatment with the genotoxic stress inducer camptothecin for 6 h favored2007-01-01T00:00:00Z2007 Oct2025-04-21T14:52:05.082Z2019-03-27T02:22:21ZS-EPMC21688951770939710.1128/mcb.00272-0710.1128/MCB.00272-07